Tags: Drug.

Edoxaban (INN codenamed DU-176b trade name Lixiana) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It is an oral once-daily direct factor Xa inhibitor under investigation for stroke prevention in patients with atrial fibrillation and for treatment and secondary prevention of venous thromboembolism. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery.

Edoxaban_skeletal.svg
ATC prefix
none
CAS number
912273-65-5
FDA UNII code
NDU3J18APO
IUPAC name
N'-(5-chloropyridin-2-yl)-N-[(1S2R4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-67-dihydro-4H-[13]thiazolo[54-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide
PubChem
25022378

Loading...

This page contains content from the copyrighted Wikipedia article "Edoxaban"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.